MY207687A - Tigit- and light-based chimeric proteins - Google Patents

Tigit- and light-based chimeric proteins

Info

Publication number
MY207687A
MY207687A MYPI2019004825A MYPI2019004825A MY207687A MY 207687 A MY207687 A MY 207687A MY PI2019004825 A MYPI2019004825 A MY PI2019004825A MY PI2019004825 A MYPI2019004825 A MY PI2019004825A MY 207687 A MY207687 A MY 207687A
Authority
MY
Malaysia
Prior art keywords
light
tigit
chimeric proteins
based chimeric
disease
Prior art date
Application number
MYPI2019004825A
Other languages
English (en)
Inventor
Taylor Schreiber
George Fromm
Silva Suresh De
Original Assignee
Shattuck Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shattuck Labs Inc filed Critical Shattuck Labs Inc
Publication of MY207687A publication Critical patent/MY207687A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MYPI2019004825A 2017-02-27 2018-02-27 Tigit- and light-based chimeric proteins MY207687A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762464002P 2017-02-27 2017-02-27
PCT/US2018/020037 WO2018157162A1 (en) 2017-02-27 2018-02-27 Tigit- and light-based chimeric proteins

Publications (1)

Publication Number Publication Date
MY207687A true MY207687A (en) 2025-03-12

Family

ID=63253416

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019004825A MY207687A (en) 2017-02-27 2018-02-27 Tigit- and light-based chimeric proteins

Country Status (15)

Country Link
US (8) US20190367579A1 (enExample)
EP (2) EP3585425A4 (enExample)
JP (5) JP7260477B2 (enExample)
KR (1) KR102745835B1 (enExample)
CN (3) CN110234345A (enExample)
AU (2) AU2018223821B2 (enExample)
BR (1) BR112019017298A2 (enExample)
CA (2) CA3054133A1 (enExample)
IL (2) IL268198B2 (enExample)
MX (1) MX2019009812A (enExample)
MY (1) MY207687A (enExample)
PH (1) PH12019501533A1 (enExample)
SG (1) SG11201906465YA (enExample)
WO (2) WO2018157162A1 (enExample)
ZA (1) ZA201905488B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL268198B2 (en) * 2017-02-27 2024-10-01 Shattuck Labs Inc Tigit- and light-based chimeric proteins
WO2019067502A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. METHODS FOR IMPROVING CARDIOVASCULAR FUNCTION AND TREATING CARDIOVASCULAR DISEASE USING RECOMBINANT ECTO-NUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE
AU2019290192A1 (en) * 2018-06-21 2021-01-07 Shattuck Labs, Inc. Heterodimeric proteins and uses thereof
AU2019333173A1 (en) * 2018-08-29 2021-03-11 Shattuck Labs, Inc. Combination therapies
AU2019328305A1 (en) * 2018-08-29 2021-03-04 Shattuck Labs, Inc. Combination therapies comprising tim-3-based chimeric proteins
WO2020047328A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Combination therapies comprising pd-1-based chimeric proteins
AU2019327572B2 (en) 2018-08-31 2025-11-13 Yale University ENPP1 polypeptides and methods of using same
EP3846829A4 (en) * 2018-09-05 2022-09-14 Arizona Board of Regents on behalf of Arizona State University ONCOLYTIC VIRUS PLATFORM FOR THE TREATMENT OF HEMATOLOGICAL CANCER
EP4079750A3 (en) 2018-11-21 2023-01-04 Mayo Foundation for Medical Education and Research Adenoviruses and methods for using adenoviruses
CA3131259A1 (en) * 2019-02-28 2020-09-03 Shattuck Labs, Inc. Combination therapies
IL292788B2 (en) * 2019-04-29 2023-12-01 Mayo Found Medical Education & Res Multivalent pd-l1 binding compounds for treating cancer
CN112111437B (zh) * 2020-05-25 2023-09-05 江南大学 2’-岩藻糖基乳糖产量提高的重组枯草芽孢杆菌及其构建方法
CR20220611A (es) * 2020-06-02 2023-06-07 Arcus Biosciences Inc Anticuerpos anti-tigit
IL298946A (en) 2020-06-18 2023-02-01 Genentech Inc Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
CN111808800B (zh) * 2020-07-20 2022-08-26 中南大学湘雅二医院 一种体外诱导免疫抑制性髓系抑制细胞及其制备和应用
JP2023541996A (ja) * 2020-09-17 2023-10-04 シャタック ラボ，インコーポレイテッド ＳＩＲＰ１αキメラタンパク質の臨床投与
WO2022094482A1 (en) * 2020-11-02 2022-05-05 Athae Bio, Inc. Two-domain multimeric fusion proteins
JP2024500065A (ja) * 2020-12-03 2024-01-04 シャタック ラボ，インコーポレイテッド Ｔｉｇｉｔベースのキメラタンパク質及びｌｉｇｈｔベースのキメラタンパク質を使用してがんを処置する方法
WO2022179567A1 (zh) * 2021-02-24 2022-09-01 克莱格医学有限公司 Tigit工程化细胞及其组合物
CN115260312B (zh) * 2021-04-30 2025-02-14 保诺科技（北京）有限公司 结合ox40的抗体或抗原结合片段
JP2024527049A (ja) 2021-07-28 2024-07-19 ジェネンテック， インコーポレイテッド がんを治療するための方法及び組成物
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
CN115960247A (zh) * 2021-10-13 2023-04-14 苏州科锐迈德生物医药科技有限公司 基于t7rna聚合酶的融合多肽及其制备方法、用途
CA3236815A1 (en) * 2021-11-01 2023-05-04 Shattuck Labs, Inc. Chimeric proteins for treating cutaneous inflammation
CN114209815B (zh) * 2021-11-22 2024-04-26 山东大学 一种药物组合物及其制备方法和应用
WO2023105281A1 (en) * 2021-12-11 2023-06-15 Fundaciò Privada Institut De Recerca De La Sida-Caixa Soluble tigit recombinant proteins
CN115490771A (zh) * 2021-12-24 2022-12-20 合肥天港免疫药物有限公司 重组抗体及其应用
CN114196691B (zh) * 2021-12-28 2023-08-11 重庆澳龙生物制品有限公司 一种制备防治牛、羊棘球蚴病多表位重组疫苗的基因、蛋白质、疫苗和应用
IL317449A (en) 2022-06-07 2025-02-01 Genentech Inc Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
CN117624375A (zh) * 2022-08-30 2024-03-01 北京卡替医疗技术有限公司 增强受体、表达增强受体的免疫细胞及其用途
CN116350748A (zh) * 2022-11-01 2023-06-30 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) Tigit融合蛋白在制备用于治疗系统性红斑狼疮药物中的应用
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
CN116041542B (zh) * 2022-12-06 2026-02-17 上海恩凯细胞技术有限公司 逆转肿瘤微环境抑制性信号的nk细胞制备方法及应用
CN116037072B (zh) * 2023-02-24 2025-01-03 宁夏医科大学 一种血清抗体亲和分离材料的制备方法与应用
CN116925236B (zh) * 2023-05-12 2024-06-04 上海恩凯细胞技术有限公司 嵌合转换受体及其应用
AU2024314312A1 (en) * 2023-06-22 2025-10-30 Fbd Biologics Limited Multi-targeting protein complex and methods of use thereof
CN116982600B (zh) * 2023-09-14 2025-11-18 江苏集萃药康生物科技股份有限公司 一种cd69人源化小鼠模型的构建方法及其应用
CN119930791A (zh) * 2023-11-02 2025-05-06 重庆精准生物技术有限公司 特异性tigit肽段
WO2025140345A1 (zh) * 2023-12-29 2025-07-03 沈阳三生制药有限责任公司 一种tigit多肽及tigit/ctla4融合蛋白

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
DE69233051T2 (de) 1991-10-25 2004-03-11 Immunex Corp., Seattle Antikörper gegen CD40-L
WO2001049318A1 (en) 2000-01-03 2001-07-12 Tr Associates, L.L.C. Novel chimeric proteins and methods for using the same
US20110041190A1 (en) 2002-10-31 2011-02-17 Tykocinski Mark L Novel chimeric proteins
US7696168B2 (en) 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
MXPA06003686A (es) 2003-10-03 2007-03-01 Brigham & Womens Hospital Ligandos tim-3 y sus metodos.
JP2007531513A (ja) 2003-11-13 2007-11-08 ハンミ ファーム．インダストリー カンパニー リミテッド 薬物のキャリアとして有用なＩｇＧＦｃ断片およびその製造方法
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
WO2007133811A2 (en) 2006-05-15 2007-11-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
EP2038303A2 (en) 2006-06-21 2009-03-25 Genentech, Inc. Crystal structure of ox40l and ox40l complexed with ox40 receptor
WO2008061377A1 (en) 2006-11-22 2008-05-29 Centre Hospitalier De L'universite De Montreal Novel receptor for cd40l and uses thereof
US8263081B2 (en) 2007-05-14 2012-09-11 The University Of Chicago Antibody-light fusion products for cancer therapeutics
FI3056514T4 (fi) 2008-01-15 2025-10-06 Univ Leland Stanford Junior Menetelmät cd47:n välittämän fagosytoosin manipuloimiseksi
EP2262531A1 (en) 2008-03-08 2010-12-22 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
JP5475766B2 (ja) 2008-06-30 2014-04-16 ユニバーシティ オブ ペンシルベニア Ｆｎ１４／ＴＲＡＩＬ融合タンパク質
WO2010003118A1 (en) 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Tgf-b antagonist multi-target binding proteins
ES2571879T3 (es) 2008-07-21 2016-05-27 Apogenix Ag Moléculas de una sola cadena de TNFSF
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
WO2010062401A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules
CN102257001A (zh) * 2008-12-19 2011-11-23 诺瓦提斯公司 治疗自体免疫和炎性病症的可溶性多肽
US9221895B2 (en) 2009-03-13 2015-12-29 The Trustees Of The University Of Pennsylvania OX40/TRAIL fusion proteins
CA3253628A1 (en) 2010-03-05 2025-11-29 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
CA2812057A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies
CN107090029B (zh) 2010-11-11 2021-07-13 港大科桥有限公司 可溶性 pd-1变体、融合构建体及其用途
EP2697257B1 (en) 2011-04-13 2016-10-19 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
US10179164B2 (en) 2011-05-25 2019-01-15 Cel-Sci Corporation Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions
CN102850458B (zh) * 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途
CA2842368A1 (en) 2011-07-29 2013-02-07 The Trustees Of The University Of Pennsylvania Switch costimulatory receptors
CA2863818A1 (en) 2012-02-06 2013-08-15 Brendan CURTI Cancer treatment and monitoring methods using ox40 agonists
MY174248A (en) 2012-04-30 2020-04-01 Biocon Ltd Targeted/immunomodulatory fusion proteins and methods for making same
EP4053162A1 (en) 2012-05-18 2022-09-07 Aptevo Research and Development LLC Bispecific scfv immunofusion (bif) binding to cd123 and cd3
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
US9969789B2 (en) 2012-12-17 2018-05-15 Trillium Therapeutics Inc. Treatment of CD47+ disease cells with SIRP alpha-Fc fusions
US10040841B2 (en) 2013-01-01 2018-08-07 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
US9657082B2 (en) 2013-01-31 2017-05-23 Thomas Jefferson University PD-L1 and PD-L2-based fusion proteins and uses thereof
US9834610B2 (en) 2013-01-31 2017-12-05 Thomas Jefferson University Fusion proteins for modulating regulatory and effector T cells
WO2015116178A1 (en) 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
WO2014121093A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
WO2014121099A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
EP2961831B1 (en) 2013-02-26 2020-06-10 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
CN105121474B9 (zh) 2013-03-12 2020-06-19 比奥孔有限公司 融合免疫调节蛋白及其制备方法
JP6623353B2 (ja) 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｐｄ−１抗体並びにその治療及び診断のための使用
US10144770B2 (en) * 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
US10196435B2 (en) 2013-11-18 2019-02-05 University Of Southern California OX40L fusion protein for the immunotherapy of tumors of veterinary animals
CA2934028A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
WO2015104406A2 (en) 2014-01-13 2015-07-16 Pieris Ag Multi-specific polypeptide useful for localized tumor immunomodulation
WO2015107331A2 (en) 2014-01-14 2015-07-23 Kymab Limited Anti-light antibodies
EP3096782A4 (en) 2014-01-21 2017-07-26 Medlmmune, LLC Compositions and methods for modulating and redirecting immune responses
WO2015148416A1 (en) 2014-03-24 2015-10-01 Deqiang Jing Novel recombinant bi-functional fusion proteins, preparation and use thereof
US9718870B2 (en) 2014-05-29 2017-08-01 Medimmune, Llc OX40L fusion proteins and uses thereof
EP3160497A4 (en) 2014-06-27 2018-01-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Conjugates for immunotherapy
WO2016023040A1 (en) 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
SG11201700629TA (en) 2014-08-11 2017-02-27 Delinia Inc Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
AU2015303135B2 (en) 2014-08-15 2021-05-20 Merck Patent Gmbh SIRP-alpha immunoglobulin fusion proteins
MX2017006320A (es) 2014-11-17 2017-08-10 Genentech Inc Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
EP3226900A4 (en) 2014-12-05 2018-09-19 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
WO2016112983A1 (en) * 2015-01-15 2016-07-21 Biontech Ag Cytokine fusion proteins
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
KR20170109582A (ko) 2015-02-06 2017-09-29 히트 바이오로직스, 인코퍼레이티드 벡터 공동 발현 백신 및 공동 자극 분자
WO2016166139A1 (en) 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
CN114425077A (zh) 2015-05-18 2022-05-03 起源生物医药公司 Sirp多肽组合物和使用方法
CN117964732A (zh) * 2015-08-07 2024-05-03 Alx肿瘤生物技术公司 具有SIRP-α结构域或其变体的构建体
US10183060B2 (en) 2015-10-01 2019-01-22 Heat Biologics, Inc. Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins
WO2018075960A1 (en) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
IL268198B2 (en) * 2017-02-27 2024-10-01 Shattuck Labs Inc Tigit- and light-based chimeric proteins

Also Published As

Publication number Publication date
AU2022218575A1 (en) 2022-11-10
PH12019501533A1 (en) 2020-02-24
AU2018223821B2 (en) 2022-05-19
EP3585425A1 (en) 2020-01-01
WO2018157162A1 (en) 2018-08-30
RU2019125682A (ru) 2021-03-29
IL268198A (en) 2019-09-26
MX2019009812A (es) 2019-10-14
US20220315637A1 (en) 2022-10-06
IL268198B2 (en) 2024-10-01
US10899817B2 (en) 2021-01-26
JP2020508329A (ja) 2020-03-19
EP3585418A1 (en) 2020-01-01
US12071465B2 (en) 2024-08-27
CN110234345A (zh) 2019-09-13
JP7128195B2 (ja) 2022-08-30
JP7260477B2 (ja) 2023-04-18
CN118994414A (zh) 2024-11-22
KR102745835B1 (ko) 2024-12-24
US10927159B2 (en) 2021-02-23
CA3054127A1 (en) 2018-08-30
US20190367579A1 (en) 2019-12-05
CN110381983A (zh) 2019-10-25
US20220227831A1 (en) 2022-07-21
US11332509B2 (en) 2022-05-17
AU2018223821A1 (en) 2019-07-11
RU2019125682A3 (enExample) 2021-12-03
EP3585425A4 (en) 2020-10-28
US20240190939A1 (en) 2024-06-13
JP7620045B2 (ja) 2025-01-22
EP3585418A4 (en) 2020-11-25
WO2018157165A1 (en) 2018-08-30
IL313003A (en) 2024-07-01
SG11201906465YA (en) 2019-08-27
JP2022159510A (ja) 2022-10-17
CN110381983B (zh) 2024-07-09
JP2025061180A (ja) 2025-04-10
JP2020508068A (ja) 2020-03-19
KR20190122667A (ko) 2019-10-30
US20200283496A1 (en) 2020-09-10
CA3054133A1 (en) 2018-03-30
US20200399342A1 (en) 2020-12-24
ZA201905488B (en) 2024-02-28
US20240368242A1 (en) 2024-11-07
JP2023076695A (ja) 2023-06-01
BR112019017298A2 (pt) 2020-04-14
US20200222503A1 (en) 2020-07-16
IL268198B1 (en) 2024-06-01

Similar Documents

Publication Publication Date Title
ZA201905488B (en) Tigit- and light-based chimeric proteins
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
ZA201801852B (en) Anti¿pd¿1 antibodies and compositions
MY203971A (en) Anti-lag-3 antibodies and compositions
MX2022001105A (es) Anticuerpos anti tigit.
MX2022003891A (es) Anticuerpos anti-muc16 y sus usos.
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
PH12018500578A1 (en) Methods of treating inflammatory diseases
MY199711A (en) Bicyclic heterocycles as fgfr inhibitors
SG10201908028SA (en) Cyclopropylamines as lsd1 inhibitors
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12016501838A1 (en) Compounds and their methods of use
MX383947B (es) Composiciones de colágeno 7 y métodos para usar las mismas.
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
MY182809A (en) Compositions for the treatment of kidney and/or liver disease
HK1242965A1 (en) Apilimod for use in the treatment of colorectal cancer
EA201691907A1 (ru) Комбинированная терапия кураксинами